诺迪康品牌怎么样 申请店铺

我要投票 诺迪康在中草药行业中的票数:160 更新时间:2025-02-05
诺迪康是哪个国家的品牌?「诺迪康」是 西藏诺迪康药业股份有限公司 旗下著名品牌。该品牌发源于西藏,由创始人陈达彬在1999-07-14期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
诺迪康怎么样

西藏诺迪康药业股份有限公司是西藏雪域高原上诞生的第一家高新技术制药上市企业,于1999年7月14日创立,1999年7月21日在上海证券交易所上网交易,股票名称:西藏药业,股票代码:600211。

在各级领导的关心和支持下,公司已经发展成为一家拥有员工4000余人,总资产8.2亿元的现代化制药企业。公司累计上缴税金2亿余元,发放员工工资、福利2.2亿余元;公司主要产品诺迪康胶囊年销售额逾亿元,公司生物一类新药重组人脑利钠肽也已经上市销售。

公司拥有西藏诺迪康医药有限公司、成都诺迪康生物制药有限公司、四川诺迪康威光制药有限公司、西藏康达药业有限公司、西藏诺迪康藏药材开发有限公司、四川本草堂药业有限公司等下属子公司。

公司秉承“科学成就健康,健康成就未来”的理念,以科技兴业。在为藏药现代化不遗余力的同时,公司注巨资于生物制品和传统药品的研发,并构建了林芝种植基地和四个生产基地及覆盖全国的营销网络。产品涵盖生物制品、藏药和中药、化学药的产品系列,奠定了西藏药业持续发展的基础,其中具有自主知识产权的生物制品一类新药新活素,代表着目前国际急性心衰急救治疗药物的最高水平,填补了该领域的国内空白。

公司上市以来连续被西藏自治区认定为高新技术企业、西藏自治区农牧业龙头企业,2001年被国家科学技术部认定为国家火炬计划重点高新技术企业。2008年公司被科技部认定为创新型试点企业。公司图形商标(祥云图)经国家工商总局认定为中国驰名商标,公司产品诺迪康胶囊和十味蒂达胶囊被评为国家中药保护品种,同时,还被国家保密局、科学技术部评为秘密级国家秘密技术。

经过多年来的不懈努力,公司已成为拥有一个国家级企业技术中心、四个符合GMP规范的药品生产基地、一个符合GAP藏药材种植基地及覆盖全国的营销网络,集藏药产品、植物药产品、化学药产品、生物制品研发、生产和销售一体的现代化企业。

Tibet nordikang Pharmaceutical Co., Ltd. is the first high-tech pharmaceutical listed enterprise born on the snow capped plateau of Tibet. It was founded on July 14, 1999 and traded on the Internet at Shanghai Stock Exchange on July 21, 1999. Its stock name is Tibet pharmaceutical, and its stock code is 600211. With the concern and support of leaders at all levels, the company has developed into a modern pharmaceutical enterprise with more than 4000 employees and total assets of 820 million yuan. The company has paid taxes of more than 200 million yuan and paid employees salaries and welfare of more than 220 million yuan; the annual sales volume of the company's main product, nordicon capsule, is more than 100 million yuan, and the company's new biological class I recombinant human brain natriuretic peptide has also been listed for sale. The company has subsidiaries including Tibet nordikang Pharmaceutical Co., Ltd., Chengdu nordikang biopharmaceutical Co., Ltd., Sichuan nordikang Weiguang Pharmaceutical Co., Ltd., Tibet Kangda Pharmaceutical Co., Ltd., Tibet nordikang Tibetan Medicine Development Co., Ltd., Sichuan bencaotang Pharmaceutical Co., Ltd. The company adheres to the concept of "science makes health, health makes future", and prospers with science and technology. While sparing no effort for the modernization of Tibetan medicine, the company has invested heavily in the research and development of biological products and traditional drugs, and has built the Linzhi planting base, four production bases and a nationwide marketing network. The products range from biological products, Tibetan medicine, traditional Chinese medicine and chemical medicine, laying the foundation for the sustainable development of Tibetan pharmaceutical industry, among which the biological products with independent intellectual property rights represent the highest level of international emergency treatment drugs for acute heart failure, and fill the domestic gap in this field. Since its listing, the company has been successively recognized as a high-tech enterprise in Tibet Autonomous Region, a leading enterprise in agriculture and animal husbandry in Tibet Autonomous Region, and a key high-tech enterprise in the national torch plan by the Ministry of science and technology of the people's Republic of China in 2001. In 2008, the company was recognized as an innovative pilot enterprise by the Ministry of science and technology. The company's graphic trademark (xiangyuntu) has been recognized as a well-known trademark in China by the State Administration of industry and commerce. The company's products, nordikang capsule and Shiweidida capsule, have been rated as the national traditional Chinese medicine protected varieties. Meanwhile, they have also been rated as the secret level national secret technology by the State Security Bureau and the Ministry of science and technology. After years of unremitting efforts, the company has become a modern enterprise with a national enterprise technology center, four GMP compliant pharmaceutical production bases, a gap compliant Tibetan medicine planting base and a nationwide marketing network, which integrates the research and development, production and sales of Tibetan medicine products, botanical medicine products, chemical medicine products and biological products.

本文链接: https://brand.waitui.com/0b45a7af1.html 联系电话:08916835752

千城特选小程序码

7×24h 快讯

美股大型科技股盘前多数下跌,谷歌跌超7%

36氪获悉,美股大型科技股盘前多数下跌,截至发稿,谷歌跌超7%,亚马逊、苹果跌超1%,特斯拉跌0.92%,微软跌0.36%,Meta跌0.35%,奈飞跌0.14%;英伟达涨近1%。

12分钟前

热门中概股美股盘前多数走弱,拼多多跌超7%

36氪获悉,热门中概股美股盘前多数走弱,截至发稿,拼多多跌超7%,理想汽车、微博跌超3%,阿里巴巴、京东、百度、蔚来跌超2%,小鹏汽车、爱奇艺跌超1%;B站涨超1%。

12分钟前

君实生物:AWT020注射用无菌粉末临床试验申请获批

36氪获悉,君实生物公告,近日,公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,AWT020注射用无菌粉末(项目代号“JS213”)的临床试验申请获得批准。JS213是PD-1和白细胞介素-2双功能性抗体融合蛋白,主要用于晚期恶性肿瘤的治疗。

12分钟前

渣打集团任命Maria Ramos接替韦浩思担任集团主席

2月4日,渣打集团董事会宣布,鉴于韦浩思(José Viñals)已接近他服务满9年的任期,已任命Maria Ramos(65岁)接替韦浩思担任集团主席。待取得监管批准后,Maria将于公司在2025年5月8日举行的2025年股东周年大会后履新,而韦浩思届时将自董事会退任。(界面)

12分钟前

三六零:公司暂未向DeepSeek提供任何服务

36氪获悉,三六零公告,公司股票于2025年1月24日、1月27日、2月5日连续三个交易日内收盘价格涨幅偏离值累计超过20%,属于股票交易异常波动情形。经自查,公司注意到相关平台将公司股票纳入DeepSeek概念股。公司就相关事项澄清说明如下:在DeepSeek基于MIT开源协议的生态环境下,公司旗下的部分产品进行了DeepSeek的接入与本地化部署;公司暂未向DeepSeek提供任何服务。除上述事项外,公司未发现其他可能对公司股票交易价格产生较大影响的、需要公司澄清或回应的媒体报道或市场传闻

12分钟前

本页详细列出关于前列康的品牌信息,含品牌所属公司介绍,前列康所处行业的品牌地位及优势。
咨询